Description
Novo Holdings is one of the key players in the international life science investment industry. Our portfolio spans the entire range of life science development – from early-stage research to large and mature commercial players.

We are looking for a motivated Junior Analyst to support the Venture Investments team in investment analysis and administrative tasks out of our Copenhagen office, located in Hellerup.

Venture Investments is one of the most active venture capital investors in the life science industry globally. Currently, Venture Investments’ portfolio consists of biotech companies in both Europe and the US, ranging from preclinical start-ups to publicly traded companies.

We offer an opportunity for professional and personal development in a dynamic and ambitious work environment. The job provides an excellent opportunity to learn about venture capital, drug development, and investment analysis of life science companies through scientific, clinical, regulatory and commercial assessment.

The Role
The role as Junior Analyst provides exposure to venture capital, biotech and drug development, while allowing the successful candidate to work alongside and learn from an international team of seasoned life science investors.

The primary role of the Junior Analyst will be to support the European investment team through deal flow administration and investment due diligence. Additional activities include screening of new companies, participating in global team meetings, as well as various ad-hoc tasks. The role will provide exposure to biotech companies spanning a range of therapeutic areas and stages of development.

The Junior Analyst will be expected to be in the office 15-20 hours per week in our Copenhagen office, with flexibility provided for study and exam commitments.

Professional qualifications:

• 3rd year Bachelor’s student or 1st year Master’s student within natural life sciences, biomedical sciences, medicine, biomedical engineering, or similar
• Sufficient scientific literacy to read primary research literature
• Basic understanding of drug development and the pharmaceutical industry
• Demonstrated interest in commercial application of scientific research, biotech, entrepreneurship or venture capital
• Basic understanding of finance and venture capital is advantageous, but not a prerequisite
• Record of excellent academic performance
• Fluent communication in English – verbal as well as written
• Experience and proficiency with Microsoft Office and AI tools, any experience with Salesforce CRM is an advantage

Personal characteristics:

• Excellent analytical skills with the right combination of overview and attention to details
• Strong communicator in both verbal and written formats; ability to distill complex topics into concise actionable insights
• Able to work structured and independently
• Highly motivated self-starter
• Intellectually curious, with a passion for science and technology
• Team player who wants to be a part of an international environment

Working at Novo Holdings
Novo Holdings is a purpose-driven organisation where our working environment is guided by our purpose and values. We strive to create an inclusive, development-focused culture. With a team of over 200 professionals from various nationalities and diverse backgrounds, we are committed to fostering professional growth and delivering meaningful impact.

Application and Information
For more information, please contact Simon Burr via e-mail at [email protected].

Application deadline is June 26th, 2026 with an anticipated start date in September 2026. To apply, please send your CV, cover letter (maximum 350 words), and grade transcripts from high school and onward by clicking on the “Apply” button.

About Novo Holdings A/S.

Novo Holdings is a holding and investment company responsible for managing the assets and wealth of the Novo Nordisk Foundation. Our purpose is to improve people’s health and the sustainability of society and the planet by generating attractive long-term returns on the Foundation’s assets.

Novo Holdings is headquartered in Copenhagen, Denmark, with additional offices in San Francisco, Boston, London, Singapore, Shanghai, and Mumbai. Novo Holdings is a leading global life sciences investor, investing in life science companies at all stages of development, with a portfolio of more than 170 companies. In addition to its life sciences activities, Novo Holdings manages a broad portfolio of public and private assets. As of year-end 2025, Novo Holdings had total assets of EUR 93 billion.

For further information, please visit www.novoholdings.dk

Copenhagen